Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Wang, Lixia; Wang, Hongliang; Huang, Jiao; Chu, Tianzhe; Peng, Cheng; Zhang, Hai; Chen, Hulan; Xiong, Yongai; Tan, Yuzhu

doi:10.1016/j.phytochem.2022.113326

Cited by 29 publications

(18 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phillyrin is a kind of furofuran lignan, 29 and its special bicyclic oxygen structure leads to its poor water solubility. Embedding CDs is a popular strategy to increase the aqueous solubility of naturally occurring active ingredients.…”

Section: Resultsmentioning

confidence: 99%

Preparation of phillyrin/cyclodextrin inclusion complexes and study of their physical properties, solubility enhancement, molecular docking and antioxidant activity

Qin,

Zhao,

et al. 2023

New J. Chem.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Preparation of phillyrin/cyclodextrin inclusion complexes and study of their physical properties, solubility enhancement, molecular docking and antioxidant activity

Qin,

Zhao,

et al. 2023

New J. Chem.

View full text Add to dashboard Cite

show abstract

“…Lignans have been isolated from natural sources such as plants, microorganisms, etc., and have been prepared by employing different synthetic strategies. Chemists and pharmacologists, along with many pharmaceuticals, are interested in exploring the therapeutic use of lignans as they have been proven to be effective antibacterial, antifungal, antiviral, antioxidant, anticancer and anti‐inflammatory agents (Wang et al., 2022).…”

Section: Introductionmentioning

confidence: 99%

Computational analysis followed by in vitro studies to explore cytokines (TNF‐α, IL‐6 and IL‐1β) inhibition potential of the new natural molecule polonilignan

Pal,

Lakshmi Soukya,

Gupta

et al. 2024

Chem Biol Drug Des

View full text Add to dashboard Cite

Targeting pro‐inflammatory cytokines and their production is found to be of therapeutic benefit for the regulation of inflammation in various chronic autoimmune diseases. Our continued efforts to discover small molecular‐weight pro‐inflammatory cytokine inhibitors resulted in identifying a novel natural lignan molecule named polonilignan, isolated from the culture broth extract of an endophytic fungus Penicillium polonicum. An in silico study (molecular docking, ADME predictions, binding free energy calculation and molecular dynamics simulation) of the polonilignan over the pro‐inflammatory cytokines proteins TNF‐α, IL‐6 and IL‐1β was performed using Schrodinger LLC software to understand the binding interactions, drug‐like properties, and stability of the ligand‐protein complex. Further, in‐vitro testing of inhibition of TNF‐α, IL‐6 and IL‐1β by polonilignan was carried out using ELISA and RT‐PCR on LPS‐induced RAW 264.7 cell lines along with the testing of nitrite production effect (Griess assay) and cytotoxicity (MTT) analysis. Under the computational study, polonilignan revealed good docking scores, binding interactions, and stability under MDS and desirable in silico ADME results over the proteins TNF‐α, IL‐1β and IL‐6. Poloniligan showed significant inhibition of IL‐1β, IL‐6 and TNF‐α with IC50 values of 2.01 μM, 6.59 μM and 42.10 μM, respectively. Also, it reduced the translocation of the NF‐κB subunit p65 to the nucleus (confocal microscopy). The mRNA expression levels of pro‐inflammatory markers IL‐1β, TNF‐α and IL‐6 levels were lowered significantly (p < .001) by the compound, and the diminution was higher with IL‐1β. Further, the lignan was non‐cytotoxic and effective in attenuating nitrite release (IC50 48.56 μM). Thus, polonilignan has been identified as a new pan‐cytokine and NO inhibitor, it is recommended to optimise a method for the synthesis of this small molecular weight lignan and explore its pharmacokinetic characteristics, toxicity and therapeutic effect under various chronic inflammatory disease models.

show abstract

“…Natural products have long been recognized as valuable sources of substances with pharmacological properties, and among them, various metabolites with antischistosomal properties have been identified. Notably, neolignans are one such example . Previous studies on Nectandra leucantha (Lauraceae), a plant species found in the Atlantic Forest biome of Brazil, have reported the antiparasitic potential of different 3- O -4′-neolignans, especially against Leishmania donovani, L.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated from Nectandra leucantha─A Preclinical Study against Schistosoma mansoni Infection

Rocha,

Cajas,

Andrade-de-Siqueira

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Schistosomiasis, a parasitic disease affecting nearly 250 million individuals globally, poses a significant health challenge. With praziquantel being the sole available treatment and its limited efficacy in early stage infections, the identification of novel bioactive compounds becomes imperative. This study examines the potential of dehydrodieugenol B (1) and its methyl ether (2), derived from the leaves of the Brazilian Nectandra leucantha plant (Lauraceae), in combatting Schistosoma mansoni infections through a preclinical approach. Initially, compound 1 displayed noteworthy in vitro antiparasitic activity with an EC 50 of 31.9 μM, showcasing low toxicity in mammalian cells and an in vivo animal model (Caenorhabditis elegans). Conversely, compound 2 exhibited no activity. In silico predictions pointed to favorable oral bioavailability and the absence of PAINS similarities. Subsequently, a single oral dose of 400 mg/kg of compound 1 or praziquantel was administered to mice infected with adult (patent infection) or immature parasites (prepatent infection). Remarkably, in prepatent infections, 1 resulted in a significant reduction (approximately 50%) in both worm and egg burden, while praziquantel reduced worm and egg numbers by 30%. The superior efficacy of dehydrodieugenol B (1) compared to praziquantel in premature infections holds the potential to advance the development of new molecular prototypes for schistosomiasis treatment.

show abstract

Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Cited by 29 publications

References 154 publications

Preparation of phillyrin/cyclodextrin inclusion complexes and study of their physical properties, solubility enhancement, molecular docking and antioxidant activity

Preparation of phillyrin/cyclodextrin inclusion complexes and study of their physical properties, solubility enhancement, molecular docking and antioxidant activity

Computational analysis followed by in vitro studies to explore cytokines (TNF‐α, IL‐6 and IL‐1β) inhibition potential of the new natural molecule polonilignan

Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated from Nectandra leucantha─A Preclinical Study against Schistosoma mansoni Infection

Contact Info

Product

Resources

About